Seniors Integrated Longitudinal CardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)

Launched by BEIJING HOSPITAL · Mar 14, 2025

Keywords

ClinConnect Summary

The SILVER-China trial is a study designed to gather important information about elderly patients (75 years and older) who have coronary heart disease (CHD). Researchers will enroll these patients from hospitals across China and collect data about their health, lifestyle, and medical history. The goal is to create a comprehensive database that will help develop better ways to predict risks related to CHD, such as the chances of a heart attack or bleeding, and to improve treatment plans for this age group. By following these patients over several years, the study aims to enhance the care and quality of life for elderly individuals dealing with heart issues.

To participate in this study, individuals need to be at least 75 years old and have been admitted to the hospital with symptoms related to coronary heart disease, such as chest pain. They should also be able to understand the study and provide consent to participate. However, those with serious non-heart-related illnesses or significant cognitive impairments cannot join. Participants can expect regular check-ups and follow-ups over the next five years, contributing to a better understanding of heart disease in older adults and ultimately helping to improve their treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ① Age requirements: Participants are ≥ 75 years old;
• • This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms
• ③ Conform to the diagnosis of coronary heart disease: meet any one of the following conditions:
• • 1. This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;
• • 2. Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;
• • 3. The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.
• • ④ Informed consent: Participants must be able to understand the content of the study, voluntarily participate in the study, and sign the informed consent form.
• Exclusion Criteria:
• • Combined with severe non-cardiovascular disease: life expectancy does not exceed 6 months, such as advanced cancer or other end-stage disease;
• • Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.